John Ternus Signals Apple’s Future with Product-First AI Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
IRVINE, Calif., May 25, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC). Investors who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 30, 2017 lead plaintiff motion deadline.
If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 were going well, and thus the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell significantly, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
